Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

医学 溃疡性结肠炎 安慰剂 内科学 临床试验 胃肠病学 临床终点 外科 疾病 病理 替代医学
作者
William J. Sandborn,Marc Ferrante,Bal Raj Bhandari,Elina Berliba,Toshifumi Hibi∥,Geert D’Haens,JAY L. TUTTLE,Kathryn A. Krueger,Stuart W. Friedrich,M. Durante,Vipin Arora,April N. Naegeli,Jochen Schmitz,Brian G. Feagan
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:20 (1): 105-115.e14 被引量:68
标识
DOI:10.1016/j.cgh.2020.09.028
摘要

BACKGROUND & AIMS: Mirikizumab is an antibody against the p19 subunit of interleukin 23 that has demonstrated clinical efficacy and was well tolerated following 12 weeks of induction treatment in a phase 2 trial of patients with moderate to severe ulcerative colitis. We present results of the open-label extended induction period in patients who did not initially respond to treatment with mirikizumab. METHODS: This study was a continuation of I6T-MC-AMAC, a double-blind trial, performed at 75 sites in 14 countries, in which patients with moderate to severe ulcerative colitis were randomly assigned to 12 weeks induction therapy with 50 mg, 200 mg, or 600 mg mirikizumab or placebo. Patients without a clinical response (a 9-point decrease in Mayo subscore of ≥2 points and ≥35% from baseline and either a decrease of rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1) at week 12 were offered the opportunity to participate in an open-label, extended induction study for another 12 weeks, in which they received either 600 mg intravenous mirikizumab (n = 20) or, following a protocol amendment, 1000 mg intravenous mirikizumab (n = 64) every 4 weeks. At week 24, patients with a clinical response continued the extension maintenance period and received 200 mg subcutaneous mirikizumab. Endpoints included clinical remission (Mayo subscores of 0 for rectal bleeding, 0 or 1 with a 1-point decrease from baseline), clinical response, endoscopic remission (Mayo endoscopic subscore of 0), or endoscopic improvement (endoscopic subscore of 0 or 1), at study weeks 24 and 52. Data were analysed for patients who received mirikizumab or placebo during the induction phase of the study. RESULTS: Among participants who did not respond to induction mirikizumab, 50.0% of those who received the 12-week extension of 600 mg mirikizumab and 43.8% who received the extension of 1000 mg mirikizumab achieved a clinical response; 15.0% and 9.4% achieved clinical remission, respectively. Endoscopic improvement was achieved by 20.0% of subjects in the 600 mg mirikizumab group and 15.6% subjects in the 1000 mg mirikizumab group. Among initial nonresponders to mirikizumab who had clinical response at study week 24 and continued into maintenance therapy, 65.8% maintained the clinical response, 26.3% achieved clinical remission, and 34.2% had endoscopic improvement at week 52. No new safety concerns were identified. CONCLUSIONS: Extended doses of mirikizumab (600 mg and 1000 mg) for an additional 12 weeks produce a clinical response in up to 50% of patients who did not have a clinical response to 12 weeks of induction doses (50 mg, 200 mg, or 600 mg). Most of the responders to the extended doses maintained clinical response for up to 52 weeks. Clinicaltrials.gov no: NCT02589665.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我爱科研发布了新的文献求助10
刚刚
jeery完成签到 ,获得积分10
1秒前
哈哈哈完成签到,获得积分10
1秒前
黑包包大人完成签到,获得积分10
2秒前
山海不远完成签到,获得积分10
2秒前
白昼学派完成签到,获得积分10
2秒前
飞翔的鸣完成签到,获得积分10
2秒前
tkai发布了新的文献求助10
2秒前
玥来玥好完成签到,获得积分10
2秒前
hao2023完成签到,获得积分10
3秒前
健忘的星星完成签到,获得积分10
3秒前
Lucas的应助被勤恳夏旋采纳,获得10
4秒前
tszjw168发布了新的文献求助10
4秒前
5秒前
迪仔完成签到 ,获得积分10
5秒前
xiaomi完成签到,获得积分10
5秒前
zhaozhao完成签到,获得积分10
6秒前
王旭倩完成签到 ,获得积分10
6秒前
zxy完成签到 ,获得积分10
6秒前
留胡子的手机完成签到,获得积分10
6秒前
781473059完成签到,获得积分10
7秒前
Jimmy完成签到,获得积分10
7秒前
WANG01DU完成签到,获得积分10
8秒前
欧阳完成签到,获得积分10
8秒前
botao_li完成签到,获得积分10
8秒前
咩咩完成签到,获得积分10
8秒前
科研通AI6.2的应助被tszjw168采纳,获得10
9秒前
纳米酶催化完成签到,获得积分10
10秒前
yexing完成签到,获得积分10
10秒前
Kal完成签到 ,获得积分10
10秒前
清都山水郎完成签到,获得积分10
10秒前
11秒前
wen完成签到,获得积分10
11秒前
半点禅完成签到,获得积分10
11秒前
周辰完成签到,获得积分10
11秒前
79发布了新的文献求助10
11秒前
李健的小迷弟的应助被CO2采纳,获得10
12秒前
大盘菜完成签到,获得积分10
12秒前
Aaron完成签到 ,获得积分10
12秒前
刘亚军完成签到 ,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039